Abstract

Crystals can trigger a wide range of kidney injuries that may link to the development of kidney stones. Infiltrating macrophages may influence hyperoxaluria-induced intrarenal calcium oxalate (CaOx) crystals deposition, yet their linkage to sex hormones remains unclear. Here we demonstrated that suppressing the androgen receptor (AR) expression in renal tubular epithelial cells increased the macrophage recruitment/M2 polarization that may result in enhancing the phagocytosis of intrarenal CaOx crystals. Mechanism dissection suggested that AR can suppress macrophage colony-stimulating factor 1 (CSF-1) expression via increasing miRNA-185-5p expression to suppress the M2 macrophage polarization-mediated intrarenal CaOx crystals phagocytosis. The preclinical study using glyoxylate-induced intrarenal CaOx crystals deposition mouse model revealed that renal tubule-specific AR knockout mice have less intrarenal CaOx crystals deposition with more recruited M2 macrophages in the kidney compared with the wild-type mice. Results from the in vivo rat model using hydroxy-l-proline-induced CaOx crystals deposition also demonstrated that targeting the AR with ASC-J9® suppressed the intrarenal CaOx crystals deposition via increasing the renal macrophage recruitment/M2 polarization. Together, results from multiple preclinical studies using multiple in vitro cell lines and in vivo mouse/rat models all demonstrated that targeting the AR with a small molecule ASC-J9® may function via altering macrophage recruitment/M2 polarization to decrease the intrarenal CaOx crystals deposition, a key phenotype seen in many kidney stone disease patients with hyperoxaluria.

Details

Title
Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals
Author
Zhu, Wei 1 ; Zhao, Zhijian 1 ; Chou Fuju 2 ; Zuo, Li 2 ; Liu Tongzu 2 ; Yeh Shuyuan 2 ; Bushinsky, David 3 ; Zeng Guohua 4 ; Chang Chawnshang 5 

 The First Affiliated Hospital of Guangzhou Medical University, Department of Urology and Guangdong Key Laboratory of Urology, Guangzhou, China (GRID:grid.470124.4); University of Rochester Medical Center, George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and The Wilmot Cancer Institute, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
 University of Rochester Medical Center, George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and The Wilmot Cancer Institute, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
 University of Rochester Medical Center, Departments of Medicine, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166) 
 The First Affiliated Hospital of Guangzhou Medical University, Department of Urology and Guangdong Key Laboratory of Urology, Guangzhou, China (GRID:grid.470124.4) 
 University of Rochester Medical Center, George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and The Wilmot Cancer Institute, Rochester, USA (GRID:grid.412750.5) (ISNI:0000 0004 1936 9166); China Medical University/Hospital, Sex Hormone Research Center, Taichung, Taiwan (GRID:grid.411508.9) (ISNI:0000 0004 0572 9415) 
Publication year
2019
Publication date
Apr 2019
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2194569772
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.